biomarkers, tumor

Correspondence on 'Novel imaging biomarkers predict outcomes in stage III unresectable non-small cell lung cancer treated with chemoradiation and durvalumab' by Jazieh et al
Jieling Zheng, Bin Zhang

Journal for ImmunoTherapy of Cancer May 2022, 10 (5) e004965; DOI: 10.1136/jitc-2022-004965
NKG2A and PD-L1 expression panel predicts clinical benefits from adjuvant chemotherapy and PD-L1 blockade in muscle-invasive bladder cancer
Sen Yan, Han Zeng, Kaifeng Jin, Fei Shao, Zhaopei Liu, Yuan Chang, Yiwei Wang, Yu Zhu, Zewei Wang, Le Xu, Jiejie Xu

Journal for ImmunoTherapy of Cancer May 2022, 10 (5) e004569; DOI: 10.1136/jitc-2022-004569
Immune cell infiltration pattern in non-small cell lung cancer PDX models is a model immanent feature and correlates with a distinct molecular and phenotypic make-up
Eva Oswald, Daniel Bug, Anne Grote, Kanstantsin Lashuk, Nassim Bouteldja, Dorothee Lenhard, Anne Löhr, Anke Behnke, Volker Knauff, Anna Edinger, Kerstin Klingner, Simone Gaedicke, Gabriele Niedermann, Dorit Merhof, Friedrich Feuerhake, Julia Schueler

Journal for ImmunoTherapy of Cancer Apr 2022, 10 (4) e004412; DOI: 10.1136/jitc-2021-004412
Immune correlates of clinical parameters in patients with HPV-associated malignancies treated with bintrafusp alfa
Yo-Ting Tsai, Julius Strauss, Nicole J Toney, Caroline Jochems, David J Venzon, James L Gulley, Jeffrey Schlom, Renee N Donahue

Journal for ImmunoTherapy of Cancer Apr 2022, 10 (4) e004601; DOI: 10.1136/jitc-2022-004601
Subtyping of microsatellite stability colorectal cancer reveals guanylate binding protein 2 (GBP2) as a potential immunotherapeutic target
Haizhou Wang, Yabo Zhou, Yangyang Zhang, Shilin Fang, Meng Zhang, Haiou Li, Fei Xu, Lan Liu, Jing Liu, Qiu Zhao, Fan Wang

Journal for ImmunoTherapy of Cancer Apr 2022, 10 (4) e004302; DOI: 10.1136/jitc-2021-004302
Clinical, genomic, and transcriptomic correlates of response to immune checkpoint blockade-based therapy in a cohort of patients with angiosarcoma treated at a single center
Evan Rosenbaum, Cristina R Antonescu, Shaleigh Smith, Martina Bradic, Daniel Kashani, Allison L Richards, Mark Donoghue, Ciara M Kelly, Benjamin Nacev, Jason E Chan, Ping Chi, Mark A Dickson, Mary L Keohan, Mrinal M Gounder, Sujana Movva, Viswatej Avutu, Katherine Thornton, Ahmet Zehir, Anita S Bowman, Samuel Singer, William Tap, Sandra D’Angelo

Journal for ImmunoTherapy of Cancer Apr 2022, 10 (4) e004149; DOI: 10.1136/jitc-2021-004149
eEF2K promotes PD-L1 stabilization through inactivating GSK3β in melanoma
Xisha Chen, Kuansong Wang, Shilong Jiang, Hongyin Sun, Xuanling Che, Minghui Zhang, Jiaying He, Ying Wen, Mengting Liao, Xiangling Li, Xiaoming Zhou, Jianxun Song, Xingcong Ren, Wenjun Yi, Jinming Yang, Xiang Chen, Mingzhu Yin, Yan Cheng

Journal for ImmunoTherapy of Cancer Mar 2022, 10 (3) e004026; DOI: 10.1136/jitc-2021-004026
Role of mass spectrometry-based serum proteomics signatures in predicting clinical outcomes and toxicity in patients with cancer treated with immunotherapy
Yeonggyeong Park, Min Jeong Kim, Yoonhee Choi, Na Hyun Kim, Leeseul Kim, Seung Pyo Daniel Hong, Hyung-Gyo Cho, Emma Yu, Young Kwang Chae

Journal for ImmunoTherapy of Cancer Mar 2022, 10 (3) e003566; DOI: 10.1136/jitc-2021-003566
DNA methylation profiles differ in responders versus non-responders to anti-PD-1 immune checkpoint inhibitors in patients with advanced and metastatic head and neck squamous cell carcinoma
Angelika Martina Starzer, Gerwin Heller, Erwin Tomasich, Thomas Melchardt, Katharina Feldmann, Teresa Hatziioannou, Stefan Traint, Christoph Minichsdorfer, Ursula Schwarz-Nemec, Maja Nackenhorst, Leonhard Müllauer, Matthias Preusser, Anna Sophie Berghoff, Thorsten Fuereder

Journal for ImmunoTherapy of Cancer Mar 2022, 10 (3) e003420; DOI: 10.1136/jitc-2021-003420
C reactive protein flare predicts response to checkpoint inhibitor treatment in non-small cell lung cancer
Niklas Klümper, Jonas Saal, Fiamma Berner, Christa Lichtensteiger, Nina Wyss, Annkristin Heine, Franz Georg Bauernfeind, Jörg Ellinger, Peter Brossart, Stefan Diem, Sabine Schmid, Markus Joerger, Martin Frueh, Manuel Ritter, Michael Hölzel, Lukas Flatz, Tobias Bald

Journal for ImmunoTherapy of Cancer Mar 2022, 10 (3) e004024; DOI: 10.1136/jitc-2021-004024

Main menu

biomarkers, tumor

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

biomarkers, tumor

Pages